AT 1226
Alternative Names: AT-1226; AT_1226Latest Information Update: 02 Aug 2021
Price :
$50 *
At a glance
- Originator Catalan Institute of Nanoscience and Nanotechnology; Catalan Institution for Research and Advanced Studies; Germans Trias i Pujol Research Institute
- Developer Ahead Therapeutics
- Class Neuroprotectants; Phosphatidylserines; Vaccines
- Mechanism of Action Apoptosis stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Multiple sclerosis
Most Recent Events
- 29 Jul 2021 AT 1226 is available for licensing as of 29 Jul 2021. https://www.aheadtherapeutics.com/ahead-therapeutics-partnerships/
- 29 Jul 2021 Preclinical trials in Multiple sclerosis in Spain (unspecified route) before July 2021 (Ahead Therapeutics pipeline, July 2021)
- 29 Jul 2021 Interim pharmacodynamics data from a preclinical study in Multiple sclerosis released by Ahead Therapeutics